|
LipidManagement™ is certified
for CME credit. Save your quarterly issues this year, as they
will be needed for the CME posttest in December 2002.
LEARNING OBJECTIVES
After reading the articles in this issue of LipidManagement™,
participants should be able to:
| • |
Assess a patient's overweight/obesity
level accurately and monitor body-weight changes to manage
risk for cardiovascular disease |
| • |
Identify the appropriate treatment plan
for an individual's weight- control program |
| • |
Utilize current tests and
risk markers to determine the cardiac risk of an asymptomatic
patient |
Intended audience:
primary-care physicians, cardiologists, endocrinologists
Release date: September 15, 2002
End date: December 31, 2003
This CME activity is sponsored by Thomson Professional Postgraduate
Services®, Secaucus, NJ.
Thomson Professional Postgraduate Services®
is accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
Thomson Professional Postgraduate Services®
designates this educational activity for a maximum of 2 hours
in category 1 credit toward the AMA Physician's Recognition
Award. Each physician should claim only those hours of credit
that he/she actually spent in the activity.
|
|
|
The Metabolic Syndrome Tied Closely to Abdominal Obesity
According to ATP III guidelines, the diagnosis of the metabolic syndrome
is made when three or more of the following risk factors are present1:
 |
Abdominal obesity: waist circumference >40 inches in men,
>35 inches in women |
|
TG: >150 mg/dL |
|
HDL-C: <40 mg/dL in men, <50 mg/dL in women |
|
BP: >130/>85 mm Hg |
|
Fasting glucose: >110 mg/dL |
The metabolic syndrome is closely linked to insulin resistance, a
metabolic disorder whose development is promoted by excess body fat
(particularly abdominal obesity) and physical inactivity.2
The age-adjusted prevalence of the syndrome in NHANES III participants
was 23.7%.3 Dyslipidemia, hypertension,
glucose intolerance, and hypercoagulability caused by insulin resistance
predispose patients not only to diabetes but also to coronary artery
disease, myocardial infarction, and stroke.2
Weight loss, even if relatively modest (ie, 5%–10%), can greatly
reduce the risk of developing type 2 diabetes and, in turn, CVD.4
Various studies have shown that weight loss is also associated with
significant reductions in BP, lipid levels, and mortality.4
References
| 1. |
Third Report of the Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III). National
Cholesterol Education Program. National Heart, Lung, and Blood
Institute. National Institutes of Health; May 2001. NIH Publication
No. 01-3670. |
| 2. |
Giles T. Reducing the risk of
cardiovascular events through weight loss. CME article available
at: www.medscape.com/viewprogram/1870_pnt.
Accessed August 14, 2002. |
| 3. |
Ford ES, Giles WH, Dietz WH. Prevalence
of the metabolic syndrome among US adults: findings from the
third National Health and Nutrition Examination Survey. JAMA.
2002;287:356-359. |
| 4. |
Pi-Sunyer FX. The role of weight
loss in improving metabolic outcomes. CME article available
at: www.medscape.com/viewprogram/1440_pnt.
Accessed August 14, 2002. |
|